Literature DB >> 34180731

The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.

Jennifer B Gordetsky1, Kathleen W Montgomery1, Giovanna A Giannico1, Soroush Rais-Bahrami2, Prabin Thapa3, Stephen Boorjian3, Igor Frank3, John Cheville3.   

Abstract

Objectives. To compare the clinicopathologic characteristics of urothelial carcinoma (UC), urothelial carcinoma with squamous differentiation (UCSD), and squamous cell carcinoma (SCC) of the bladder, which have been suggested to differ in terms of risk factors, immunophenotype, and prognosis. Methods. We evaluated the clinicopathologic features of radical cystectomy specimens between 1980 and 2015 with a diagnosis of SCC, UCSD, and UC. PD-L1 immunohistochemistry (clinically available clones 22C3, SP142, and SP263) was performed on SCC and UCSD. Multivariate Cox regression was used to identify prognostic factors. Kaplan-Meier curves were plotted to assess cancer-specific survival (CSS). Results. Of the 1478 cases, there were 1126 UC (76%), 217 UCSD (15%), and 135 SCC (9%). Bladder cancer was more common in men than women (80% vs 20%, P < .0001). However, a higher proportion of SCC and UCSD occurred in women (SCC-36%, UCSD-22%, UC-18%). Women were significantly more likely to be never smokers in all 3 cohorts (UC: 45% vs 16%, UCSD: 44% vs 12%, SCC: 40% vs 18%, P < .0001). Patients with SCC and UCSD were at a higher pathologic stage (>pT2) at the time of cystectomy (UCSD-74%, SCC 71%, UC-44%, P < .0001) and had worse CSS compared to patients with UC (P = 0.006). SCC had higher PD-L1 scores (all clones) than UCSD (P < .0001). PD-L1 22C3 (P = .02, HR: 0.36) and SP142 scores (P = .046, HR: 0.27) predicted CSS on Kaplan-Meier analysis for SCC cases. Conclusions. UC, UCSD, and SCC are associated with different risk factors, gender distributions, and clinical outcomes. PD-L1 is expressed in SCC and UCSD, suggesting some patients may benefit from targeted therapy.

Entities:  

Keywords:  PD-L1; pathology; squamous cell carcinoma; survival; urinary bladder; urothelial carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34180731     DOI: 10.1177/10668969211027264

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  4 in total

Review 1.  [Occupation-related cancer in urology-Current knowledge including environmental medical aspects].

Authors:  Klaus Golka; Ralf Böthig; Wobbeke Weistenhöfer; Olaf P Jungmann; Steffi Bergmann; Michael Zellner; Wolfgang Schöps
Journal:  Urologie       Date:  2022-09-26

2.  Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.

Authors:  Carolyn D Hurst; Guo Cheng; Fiona M Platt; Olivia Alder; Emma Vi Black; Julie E Burns; Joanne Brown; Sunjay Jain; Jo-An Roulson; Margaret A Knowles
Journal:  J Pathol Clin Res       Date:  2022-03-14

3.  Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy.

Authors:  Jae-Hoon Chung; Chung-Un Lee; Dong-Hyeon Lee; Wan Song
Journal:  Biomedicines       Date:  2022-04-15

Review 4.  Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma - There's room for Immune Checkpoint Blockage?

Authors:  Ana C Madureira
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.